К содержанию
Dr. Tara EinullaevaMedical oncologist

Blood tests 9 min

BRCA Genetic Testing: Who Needs It and What It Changes

How inherited BRCA testing differs from tumour testing, who needs it with breast, ovarian, pancreatic or prostate cancer, and what the result means for you.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026

A BRCA test looks for changes in the BRCA1 and BRCA2 genes, which sharply raise the risk of breast, ovarian, pancreatic and prostate cancer. If you are already being treated for one of these cancers, the result may change your treatment — for example, by opening up access to PARP inhibitors. And for your relatives it shows whether they need to be checked.

An inherited test and a tumour test are different tests

This is what patients mix up most often, so I’ll start here.

An inherited (germline) test is done on blood or saliva. It looks for changes that are present in every cell of the body from birth and can be passed on to children.

A tumour (somatic) test is done on tumour tissue — usually the paraffin block from a biopsy or surgery. It looks for changes that arose in the cancer cells during life. These changes are not passed on to children.

Inherited test Tumour test
Sample Blood or saliva Tumour tissue (block)
What it finds Changes a person was born with Changes in the tumour — acquired ones, and sometimes inherited ones
What it’s for Risk for you and your relatives; choice of treatment Choice of treatment
Does it affect the family? Yes Not by itself — needs checking

A tumour test sometimes finds a change that is actually inherited. But it doesn’t replace an inherited test: if a BRCA mutation is found in the tumour, blood or saliva is tested separately and the result is discussed with a geneticist. For more on tumour testing and how targeted drugs work, see my article on targeted therapy.

How much BRCA raises the risk

According to the US National Cancer Institute (NCI), about 1 in 400 people carries a harmful change in BRCA1 or BRCA2. Here is how lifetime risk changes:

Type of cancer General population BRCA1 BRCA2
Breast cancer in women about 13% over 60% over 60%
Ovarian cancer about 1.1% 39–58% 13–29%
Pancreatic cancer about 1.7% up to 5% 5–10%
Prostate cancer (by age 80) about 10.6% 7–26% 19–61%
Breast cancer in men (by age 70) about 0.1% 0.2–1.2% 1.8–7.1%

The mutation is inherited in an autosomal dominant way: each child of a carrier — son or daughter — has a 50% chance of inheriting it. Men pass the mutation on just as women do, and this is often forgotten when a family history is taken.

Who needs the test

The criteria depend on the type of cancer. I’ll list the main ones from the ASCO and NCCN guidelines, but the final decision is made by your treating oncologist and a geneticist.

Breast cancer. Under the 2024 ASCO guideline, BRCA1/2 testing is offered to all patients with newly diagnosed breast cancer under 65. From 65 onwards — if:

  • treatment with a PARP inhibitor is being considered;
  • the tumour is triple-negative (no hormone receptors and no HER2 — I explain how this is determined in my article on IHC in breast cancer);
  • it is breast cancer in a man;
  • personal or family history suggests an inherited cause.

Testing is also offered at recurrence if a PARP inhibitor is being considered, and for a second tumour in the same or the other breast.

Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) — testing is indicated with a personal or family history of this cancer.

Pancreatic cancer — a personal history, or pancreatic cancer in a first-degree relative.

Prostate cancer — metastatic or node-positive cancer, as well as high-risk and very-high-risk cancer.

Family history. It’s worth thinking about seeing a geneticist if blood relatives have had breast cancer before 50, ovarian cancer, breast cancer in a man, pancreatic cancer or metastatic prostate cancer, or if someone in the family has already been found to carry a BRCA mutation.

Testing is not recommended for children under 18.

What a positive result changes in treatment

PARP inhibitors. These are targeted drugs taken as tablets. They are particularly effective against cancer cells in which a BRCA mutation has broken the DNA repair mechanism. They are used in breast, ovarian, pancreatic and prostate cancer — the indications depend on the type of cancer, the stage and previous treatment.

An example is early breast cancer. In the OlympiA trial, women with an inherited BRCA mutation and high-risk HER2-negative cancer, after completing surgery and chemotherapy, took the PARP inhibitor olaparib for 1 year or a placebo. After 3 years, 86.1% of patients in the olaparib group were free of disease, versus 77.3% in the placebo group; overall survival also improved. That is why, in breast cancer, it’s important to get the test result in time — before the main treatment is finished.

Extent of surgery. Carriers have a higher risk of cancer in the other breast: according to the NCI, within 20 years of a first cancer it is 30–40% with BRCA1 and about 25% with BRCA2 (about 8% in women without a mutation). So the test result may influence the decision about the extent of surgery, including preventive removal of the other breast. Preventive removal of the ovaries and fallopian tubes is also discussed, since there is still no effective screening for ovarian cancer.

Preventive operations are irreversible and don’t give 100% protection. The decision isn’t made on the day you get the result, but after seeing a geneticist, a surgeon and a gynaecologist.

What the result means for relatives

If a mutation is found in you, your blood relatives can be offered a test for that specific mutation. This test is simpler and more accurate than searching “from scratch”.

For relatives who are carriers, there are early detection programmes — for example, for women, starting breast screening earlier with MRI and mammography — and ways to lower the risk are discussed. A negative result in a relative tested for the known family mutation usually means their risk is close to that of the general population.

I usually advise not putting off the conversation with your family. It isn’t an easy conversation, and a geneticist can help you prepare for it.

Variants of uncertain significance and other genes

A VUS (variant of uncertain significance) is a change in a gene for which there isn’t yet enough data to say whether it raises risk. Under the ASCO guideline, a VUS should not change treatment. Over time these variants are reclassified, most often as harmless. So stay in touch with the doctor or laboratory that did the test.

Other genes. Today, rather than a BRCA-only test, a multigene panel is often done. ASCO highlights high-risk genes that can affect treatment and family screening: PALB2, TP53, PTEN, STK11, CDH1. Changes in PALB2, for example, are also linked to breast, ovarian and pancreatic cancer. Findings in moderate-risk genes do not affect treatment of a cancer already diagnosed, but they matter for assessing the risk of a second tumour and for relatives.

Ask your doctor exactly what was tested: the whole gene (sequencing) or only a few common mutations. In the second case, a negative result does not rule out other changes in the BRCA genes.

Genetic counselling

Genetic counselling is recommended before testing and is a must after a positive result. A geneticist will help you:

  • choose which genes to test, taking into account your own and your family history;
  • explain what a positive, negative or uncertain result means;
  • draw up a screening plan for you and your relatives.

Inherited test results usually come back in about 2–3 weeks.

Questions to ask your treating doctor

  • Is an inherited BRCA test indicated for me, given my diagnosis and family history?
  • Which test did I have — a tumour test or a blood test? The whole gene or common mutations?
  • If there is a mutation, does it change my treatment now? Am I eligible for a PARP inhibitor?
  • Does the result affect the extent of surgery?
  • Do I need to see a geneticist, and which of my relatives should be tested?

If you were diagnosed recently and aren’t sure whether you need this test or how its result might affect your treatment plan, I can review your records in a consultation.

Sources

  1. BRCA Gene Changes: Cancer Risk and Genetic Testing — National Cancer Institute (NCI), 2026
  2. Genetic Testing for Inherited Cancer Risk — National Cancer Institute (NCI), 2026
  3. ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer — The ASCO Post, 2024
  4. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer (GeneReviews) — National Library of Medicine (NIH), 2026
  5. OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer — The ASCO Post, 2022
  6. Clinical Guidelines for Germline Cancer Testing (based on NCCN Genetic/Familial High-Risk Assessment) — University of Chicago Genetic Services Laboratories, 2025

Watch me explain this on video

Short videos on my Instagram (in Russian)

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.